Cargando…

miR-34a-Mediated Survivin Inhibition Improves the Antitumor Activity of Selinexor in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive disease with limited therapeutic options. Here, we pursued a combinatorial therapeutic approach to enhance the activity of selinexor, the first-in-class XPO1 inhibitor, by miR-34a ectopic expression in human TNBC experimental models. Anti-prolife...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martini, Silvia, Zuco, Valentina, Tortoreto, Monica, Percio, Stefano, Campi, Elisa, El Bezawy, Rihan, Doldi, Valentina, Landesman, Yosef, Pennati, Marzia, Zaffaroni, Nadia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8227962/ https://www.ncbi.nlm.nih.gov/pubmed/34072442 http://dx.doi.org/10.3390/ph14060523

Ejemplares similares

Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism
por: El Bezawy, Rihan, et al.
Publicado: (2017)

miR-1272 Exerts Tumor-Suppressive Functions in Prostate Cancer via HIP1 Suppression
por: Rotundo, Federica, et al.
Publicado: (2020)

Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down‐regulation
por: Zuco, Valentina, et al.
Publicado: (2021)

SPOP Deregulation Improves the Radiation Response of Prostate Cancer Models by Impairing DNA Damage Repair
por: El Bezawy, Rihan, et al.
Publicado: (2020)

miR-205 enhances radiation sensitivity of prostate cancer cells by impairing DNA damage repair through PKCε and ZEB1 inhibition
por: El Bezawy, Rihan, et al.
Publicado: (2019)

MicroRNAs as Epigenetic Determinants of Treatment Response and Potential Therapeutic Targets in Prostate Cancer
por: Doldi, Valentina, et al.
Publicado: (2021)

Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin
por: De Cesare, Michelandrea, et al.
Publicado: (2015)

miR-550a-3p is a prognostic biomarker and exerts tumor-suppressive functions by targeting HSP90AA1 in diffuse malignant peritoneal mesothelioma
por: El Bezawy, Rihan, et al.
Publicado: (2022)

Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody
por: Martini, Silvia, et al.
Publicado: (2020)

Effectiveness of irinotecan plus trabectedin on a desmoplastic small round cell tumor patient-derived xenograft
por: Zuco, Valentina, et al.
Publicado: (2023)

Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma
por: Muz, Barbara, et al.
Publicado: (2017)

Prediction of Grade Reclassification of Prostate Cancer Patients on Active Surveillance through the Combination of a Three-miRNA Signature and Selected Clinical Variables
por: Gandellini, Paolo, et al.
Publicado: (2021)

Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia
por: Vitale, Candida, et al.
Publicado: (2023)

Synergistic Antitumor Effects of Novel HDAC Inhibitors and Paclitaxel In Vitro and In Vivo
por: Zuco, Valentina, et al.
Publicado: (2011)

PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins
por: Zuco, Valentina, et al.
Publicado: (2015)

Comparative Assessment of Antitumor Effects and Autophagy Induction as a Resistance Mechanism by Cytotoxics and EZH2 Inhibition in INI1-Negative Epithelioid Sarcoma Patient-Derived Xenograft
por: Stacchiotti, Silvia, et al.
Publicado: (2019)

Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma
por: Mittal, Sonam, et al.
Publicado: (2023)

The Nuclear Export Inhibitor Selinexor Inhibits Hypoxia Signaling Pathways And 3D Spheroid Growth Of Cancer Cells
por: Depping, Reinhard, et al.
Publicado: (2019)

Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status
por: Marijon, Hélène, et al.
Publicado: (2021)

CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts
por: De Cesare, Michelandrea, et al.
Publicado: (2016)

Telomere as a Therapeutic Target in Dedifferentiated Liposarcoma
por: Alessandrini, Irene, et al.
Publicado: (2022)

XPO1 target occupancy measurements confirm the selinexor recommended phase 2 dose
por: Crochiere, Marsha L., et al.
Publicado: (2017)

Survivin is Highly Expressed and Promotes Cell Survival in Malignant Peritoneal Mesothelioma
por: Zaffaroni, Nadia, et al.
Publicado: (2007)

Longitudinal tracking of single live cancer cells to understand cell cycle effects of the nuclear export inhibitor, selinexor
por: Marcus, Joshua M., et al.
Publicado: (2015)

Evaluation of Mediators Associated with the Inflammatory Response in Prostate Cancer Patients Undergoing Radiotherapy
por: Bedini, Nice, et al.
Publicado: (2018)

Selinexor decreases HIF-1α via inhibition of CRM1 in human osteosarcoma and hepatoma cells associated with an increased radiosensitivity
por: von Fallois, Moritz, et al.
Publicado: (2021)

Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents
por: Kashyap, Trinayan, et al.
Publicado: (2018)

Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death
por: Argueta, Christian, et al.
Publicado: (2018)

Selinexor Enhances NK Cell Activation Against Malignant B Cells via Downregulation of HLA-E
por: Fisher, Jack G., et al.
Publicado: (2021)

Selinexor inhibits growth of patient derived chordomas in vivo as a single agent and in combination with abemaciclib through diverse mechanisms
por: Walker, Christopher J., et al.
Publicado: (2022)

XPO1 inhibition with selinexor synergizes with proteasome inhibition in neuroblastoma by targeting nuclear export of IkB
por: Galinski, Basia, et al.
Publicado: (2021)

Targeting of RET oncogene by naphthalene diimide-mediated gene promoter G-quadruplex stabilization exerts anti-tumor activity in oncogene-addicted human medullary thyroid cancer
por: Lopergolo, Alessia, et al.
Publicado: (2016)

421 A Phase 1 and Randomized Phase 2 Clinical Trial of Selinexor and Temozolomide in Recurrent Glioblastoma Among Adults: The Product of a Successful Team Science Approach
por: Chow, Frances, et al.
Publicado: (2023)

A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma
por: Lassman, Andrew B., et al.
Publicado: (2022)

XPO1 inhibition by selinexor induces potent cytotoxicity against high grade bladder malignancies
por: Baek, Han Bit, et al.
Publicado: (2018)

Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo
por: Kashyap, Trinayan, et al.
Publicado: (2021)

In vivo antitumor activity of liposome-plasmid DNA encoding mutant survivin-T34A in cervical cancer
por: Qiu, Fang, et al.
Publicado: (2018)

δ‐Tocotrienol sensitizes and re‐sensitizes ovarian cancer cells to cisplatin via induction of G1 phase cell cycle arrest and ROS/MAPK‐mediated apoptosis
por: Fontana, Fabrizio, et al.
Publicado: (2021)

LEADeR role of miR-205 host gene as long noncoding RNA in prostate basal cell differentiation
por: Profumo, Valentina, et al.
Publicado: (2019)

A Case Report of a 58-Year-Old Woman with a Diagnosis of High-Risk Myeloma Refractory to Multiple Line of Therapy and Treated with Selinexor, Bortezomib, and Dexamethasone Prior to Allogeneic Stem Cell Transplantation
por: Cass, Michael, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ecf9ldfck3rt2pjmn6lpuvkbbo